Research Nester released a report titled “Hemophillia A Drugs Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers detailed overview of the global hemophilia A drugs market in terms of market segmentation by product, by route of administration, by distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Hemophilia A is a rare genetic disorder of the blood characterized by a deficiency in the production of plasma protein factor VIII, which results in a reduced clotting property of the blood. Hemophilia drugs are given to hemophilic patients in order to provide them with these clotting factors artificially. The market for hemophilia A drugs is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. The market is segmented by product, by route of administration, by distribution channel and by region. The product segment is further segmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, antifibrinolytics, desmopressin and others, out of which, the segment for plasma derived coagulation factors is anticipated to hold the largest share in the hemophilia A drugs market on account of highest usage as compared with other products. Plasma derives coagulation factors further can be segmented into factors such as factor VIII, factor IX, factor XIII, von Willebrand factor and active prothrombin complex concentrates.

Based on region, the hemophilia A drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Hemophilia A drugs market in North America is projected to hold the leading share in the market. This can be attributed to the recent advancements in the healthcare industry as well as the research and development of new drugs.

Growing Cases of Hemophilia to Increase the Demand for Effective Drugs

The cases of genetic disorders such as hemophilia have been growing significantly in the past few years and are estimated to grow further in the coming years as a result of which the market for hemophilia A drugs is anticipated to grow over the forecast period. However, the high costs associated with the drugs as well as the therapies available for hemophilia A treatment is predicted to restrain the market growth over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global hemophilia A drugs market which includes company profiling of Pfizer Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Genzyme Corporation, Grifols, S.A., CSL Behring, Octapharma AG, Aptevo Therapeutics and Ferring Pharmaceuticals. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global hemophilia A drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.